$LPCN - FDA Accepts for Filing Lipocine’s NDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021. PDUFA 8/29/16 (est) http://www.smarteranalyst.com/2015/11/02/analysts-bullish-on-biotech-giants-keryx-biopharmaceuticals-inc-kerx-and-lipocine-inc-nasdaqlpcn/